TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06126835
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
Study: NCT06126835
Drug: Advanced therapy
Normalized name: Keri Advanced Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
Study: NCT05619536
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline for injection
Study: NCT04972968
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT01000220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05622877
Drug: Qushi Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.
Study: NCT05622877
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.
Study: NCT06522945
Drug: TQD3524
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin antibiotics
Study: NCT05629494
Drug: Ibuprofen 400 mg, TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
Study: NCT06483243
Drug: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
Study: NCT06344533
Drug: JMKX003142 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Study: NCT06344533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Study: NCT05518383
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
Study: NCT05518383
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
Study: NCT05518383
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
Study: NCT05518383
Drug: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
Study: NCT05272696
Drug: Radical concurrent chemoradiotherapy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
Study: NCT05116306
Drug: Propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
Study: NCT06293040
Drug: Placebo Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.
Study: NCT05025358
Drug: LP-118 tablet
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
Study: NCT05027048
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm description above
Study: NCT04828226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
Study: NCT05901012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
Study: NCT06365008
Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
Study: NCT05353582
Drug: Preoperative systematic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of mFOLFOXIRI±Bev is administrated before CRS+HIPEC. Irinotecan165mg/m2 IV day 1, oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted. Bev will not be administrated in at the last two cycles for minimizing surgery complications.
Study: NCT00001004
Drug: Tumor Necrosis Factor
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05116202
Drug: RO7247669 2100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
Study: NCT05116202
Drug: RO7247669 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Study: NCT06649409
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 200 mg single dose on Day 2
Study: NCT05397171
Drug: AZD8853
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
Study: NCT06418477
Drug: Dara-CyBorD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis.
Study: NCT05512806
Drug: AZD5462
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD5462 orally.
Study: NCT06631482
Drug: Maintain MAP>=73
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
Study: NCT06621563
Drug: HS-20117 combined HS-20093
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-20117 + HS-20093
Study: NCT06575179
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group received volume-matched 0.9% saline infusions at identical rates.
Study: NCT04319627
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Study: NCT04319627
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Study: NCT06621043
Drug: NTI164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
Study: NCT04709185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo at 23:00-24:00 the night before AVS
Study: NCT04432090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
Study: NCT04432090
Drug: Study Medication (MBX-2982)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
Study: NCT05565001
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
Study: NCT05295979
Drug: Inflammatory skin disease formula
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDF granules (10.85g twice daily) for 12 weeks
Study: NCT05295979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules (10.85g twice daily) for 12 weeks
Study: NCT05098067
Drug: Lactated Ringers, Intravenous
Normalized name: Lactated Ringers, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000cc once
Study: NCT04995653
Drug: SER-155 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing with SER-155 placebo
Study: NCT05845567
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
Study: NCT05801575
Drug: Chinese Herbal Medicine (CHM) teabag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
Study: NCT06516055
Drug: S1B-408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with multiple monoamine activities
Study: NCT06602271
Drug: PF614 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental oxycodone prodrug
Study: NCT06602271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive medication
Study: NCT04913337
Drug: NGM707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study: NCT06617728
Drug: Intervention 2: Intravenous (IV) Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medications used for pain control, including opioids and non-opioid analgesics.
Study: NCT06579937
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
Study: NCT06315478
Drug: Clarithromycin 500Mg Tab
Normalized name: CLARITHROMYCIN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
Study: NCT06393257
Drug: Mucolytic
Normalized name: MUCOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucolytics were used in these patients.
Study: NCT04889157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
Study: NCT05970770
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
Study: NCT01273428
Drug: HP011-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06202664
Drug: Opioid Analgesic
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
Study: NCT06623929
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
Study: NCT05658055
Drug: probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
Study: NCT00000892
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06260046
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
Study: NCT06260046
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
Study: NCT06181305
Drug: estradiol valerate and letrozole
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hormone replacement therapy by estradiol valerate plus letrozole incorporation .
Study: NCT06509451
Drug: Giomer pit and fissure sealant with etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-PRG filler containig pit and fissure sealant with etching step
Study: NCT04926844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
Study: NCT05919992
Drug: Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
Study: NCT05919992
Drug: Placebo 250 mg Tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
Study: NCT05919992
Drug: Placebo (0,9% NaCl solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
Study: NCT06648876
Drug: YG1699
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg qd for 8 days
Study: NCT06648876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg qd for 8 days
Study: NCT05737576
Drug: HR011408 injection; NovoRapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
Study: NCT05737576
Drug: NovoRapid®；HR011408 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
Study: NCT05737576
Drug: HR011408 injection; NovoRapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
Study: NCT05737576
Drug: NovoRapid®；HR011408 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
Study: NCT05737576
Drug: HR011408 injection; NovoRapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.
Study: NCT05737576
Drug: HR011408 injection; NovoRapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.
Study: NCT05554913
Drug: QL0911
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
Study: NCT05554913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04477590
Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
Study: NCT05613608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm.
Study: NCT04902703
Drug: Saline - placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be administered subcutaneously, 5 days/week, for 24 weeks
Study: NCT05137847
Drug: Remitoro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT04921527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg orally once daily
Study: NCT05960227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ml of saline 0,9% for 4 hours insusion.
Study: NCT00072540
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05189093
Drug: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
Study: NCT04917458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
Study: NCT05208294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive an inactive placebo capsule.
Study: NCT06213896
Drug: Mydriatic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Study: NCT06212271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description.
Study: NCT05212701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
Study: NCT03673748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous injection of saline solution without cells
Study: NCT06204107
Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Test drug
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once
Study: NCT05458544
Drug: [177Lu]Ludotadipep 3.7 GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Study: NCT06431399
Drug: JLP-2004 qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
Study: NCT04908215
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream base for dermal application containing no active agent